Q3 25 EPS
$0.13
BEAT +287.32%
Est. $-0.07
Q3 25 Revenue
$53.8M
BEAT +30.47%
Est. $41.2M
vs S&P Since Q3 25
+274.4%
BEATING MARKET
TNGX +285.8% vs S&P +11.4%
Market Reaction
Did TNGX Beat Earnings? Q3 2025 Results
Tango Therapeutics delivered a stunning earnings reversal in Q3 2025, swinging to a profit of $0.13 per diluted share against a consensus estimate of negative $0.07, a beat of 287.32%, while revenue surged 363.6% year over year to $53.81 million, cle… Read more Tango Therapeutics delivered a stunning earnings reversal in Q3 2025, swinging to a profit of $0.13 per diluted share against a consensus estimate of negative $0.07, a beat of 287.32%, while revenue surged 363.6% year over year to $53.81 million, clearing the $41.24 million analyst estimate by 30.47%. The single engine behind those numbers was a one-time accounting event: the truncation of Tango's collaboration agreement with Gilead triggered full recognition of all remaining deferred upfront and research option-extension payments, collapsing what had been a $29.17 million net loss in Q3 2024 into net income of $15.88 million. Crucially, milestones and royalty rights on licensed programs remain intact. Looking ahead, the company enters 2026 with a focused pipeline led by vopimetostat in MTAP-deleted cancers, a pivotal pancreatic cancer trial expected to launch next year, and a cash runway extending into 2028 following a $212 million net-proceeds equity offering completed in October 2025, providing ample runway to reach those catalysts.
Key Takeaways
- • Recognition of all remaining deferred revenue from Gilead collaboration truncation drove Q3 2025 revenue to $53.8 million
- • Reduced R&D expenses from discontinuation of TNG908 and TNG348 programs
- • Lower G&A expenses from decreased personnel-related and external legal/patent costs
TNGX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
TNGX Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult-to-treat MTAP-del cancers, beginning with pancreatic cancer.”
— Barbara Weber, Q3 2025 Earnings Press Release
TNGX Earnings Trends
TNGX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TNGX EPS Trend
Earnings per share: estimate vs actual
TNGX Revenue Trend
Quarterly revenue: estimate vs actual
TNGX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.31 | $-0.32 | -1.72% | $0 | -100.00% |
| Q4 25 BEAT FY | $-0.33 | $-0.29 | +11.83% | $0 | -100.00% |
| FY Full Year | $-0.90 | $-0.87 | +3.10% | $62.4M | -0.81% |
| Q3 25 BEAT | $-0.07 | $0.13 | +287.32% | $53.8M | +30.47% |
| Q2 25 MISS | $-0.34 | $-0.35 | -1.92% | $3.2M | -52.55% |
| Q1 25 MISS | $-0.35 | $-0.36 | -4.08% | $5.4M | -19.84% |